Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NovaBridge Biosciences (NBP : NSDQ)

• Company Description    NovaBridge Biosciences is a biotechnology platform company committed to accelerating access to innovative medicines. NovaBridge Biosciences, formerly known as I-MAB, is based in ROCKVILLE, Md. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $3.98 Daily Weekly Monthly 20 Day Moving Average: 458,714 shares Shares Outstanding: 115.27 (millions) Market Capitalization: $458.76 (millions) Beta: 1.58 52 Week High: $6.79 52 Week Low: $0.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.25% -0.08% 12 Week -17.94% -19.26% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2440 RESEARCH BLVD SUITE 400 - ROCKVILLE,MD 20850 USA ph: 301-670-2800 fax: - ir@imabbio.com https://ir.i-mabbiopharma.com

• General Corporate Information    Officers Xi-Yong (Sean) Fu - Chief Executive Officer and Director Wei Fu - Chairperson of the Board of Directors Joseph Skelton - Chief Financial Officer Lielie Zhang - Director Chun Kwok Alan Au - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44975P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 04/02/26 Share - Related Items Shares Outstanding: 115.27 Most Recent Split Date: (:1) Beta: 1.58 Market Capitalization: $458.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.77 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -75.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - -19.65 ROA 12/31/25 - - 09/30/25 - - 06/30/25 - -18.58 Current Ratio 12/31/25 - - 09/30/25 - 14.47 06/30/25 - 22.82 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 22.82 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 2.25 06/30/25 - 2.41 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - 0.00

Powered by Zacks Investment Research ©